MedPath

LEVETIRACETAM

These highlights do not include all the information needed to use LEVETIRACETAM EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for LEVETIRACETAM EXTENDED-RELEASE TABLETS. LEVETIRACETAM extended-release tablets, for oral useInitial U.S. Approval: 1999

Approved
Approval ID

5d3ce612-94de-4ad3-b873-27cb09304d45

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 23, 2020

Manufacturers
FDA

Changzhou Pharmaceutical Factory

DUNS: 653881060

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

LEVETIRACETAM

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code55488-0519
Application NumberANDA212688
Product Classification
M
Marketing Category
C73584
G
Generic Name
LEVETIRACETAM
Product Specifications
Route of AdministrationORAL
Effective DateJune 23, 2020
FDA Product Classification

INGREDIENTS (7)

LEVETIRACETAMActive
Quantity: 750 mg in 1 1
Code: 44YRR34555
Classification: ACTIB
HYPROMELLOSE 2208 (100000 MPA.S)Inactive
Code: VM7F0B23ZI
Classification: IACT
HYPROMELLOSE 2910 (6 MPA.S)Inactive
Code: 0WZ8WG20P6
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
TRIACETINInactive
Code: XHX3C3X673
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LEVETIRACETAM - FDA Drug Approval Details